The evidence-based path of perioperative anticoagulation therapy for acute coronary syndrome
-
摘要: 抗栓治疗是急性冠状动脉综合征药物治疗的基石，围术期抗凝治疗对于预防血栓形成和降低缺血事件风险至关重要。自二十世纪九十年代以来，国际上围绕急性冠状动脉综合征患者冠状动脉介入术前、术中、术后乃至稳定期和慢性期开展了大量循证医学研究，为指导科学合理用药打下了坚实的证据基础。深入了解抗凝药物的药理特性，充分了解和正确评价临床研究结果，动态评估患者的缺血和出血风险，并结合冠状动脉病变和介入操作和并发症等情况，有利于及时调整抗栓治疗方案，从而实现安全抗栓和最大获益。Abstract: Antithrombotic therapy is the cornerstone of drug treatment for acute coronary syndrome, and perioperative anticoagulant therapy is crucial for preventing thrombosis and reducing the risk of ischemic events. Since the 1990 s, a large number of evidence-based studies have been conducted internationally on patients with acute coronary syndrome before, during, and after coronary intervention, and even in the stable and chronic phases, laying a solid evidence foundation for guiding scientific and rational drug use. In-depth understanding of the pharmacological properties of anticoagulants, full understanding and correct evaluation of clinical research results, dynamic assessment of patients' ischemic and bleeding risks, and combined with coronary artery lesions, interventional procedures, and complications will help to timely adjust antithrombotic treatment plans, thereby achieving safe antithrombotic treatment and maximum benefit.
-
Key words:
- acute coronary syndrome /
- anticoagulation therapy /
- perioperative
-
-
[1] Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial[J]. Lancet, 2011, 378(9792): 693-703. doi: 10.1016/S0140-6736(11)60876-3
[2] Silvain J, Beygui F, Barthélémy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis[J]. BMJ, 2012, 344: e553. doi: 10.1136/bmj.e553
[3] Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction[J]. N Engl J Med, 2008, 358(21): 2218-2230. doi: 10.1056/NEJMoa0708191
[4] Steg PG, van 't Hof A, Clemmensen P, et al. Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial(EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary intervention[J]. Am Heart J, 2013, 166(6): 960-967. doi: 10.1016/j.ahj.2013.08.025
[5] Zeymer U, van't Hof A, Adgey J, et al. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial[J]. Eur Heart J, 2014, 35(36): 2460-2467. doi: 10.1093/eurheartj/ehu214
[6] Han Y, Guo J, Zheng Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial[J]. JAMA, 2015, 313(13): 1336-1346. doi: 10.1001/jama.2015.2323
[7] Shah R, Rogers KC, Ahmed AJ, et al. Effect of Post-Primary Percutaneous Coronary Intervention Bivalirudin Infusion on Acute Stent Thrombosis: Meta-Analysis of Randomized Controlled Trials[J]. JACC Cardiovasc Interv, 2016, 9(13): 1313-1320. doi: 10.1016/j.jcin.2016.03.031
[8] Li Y, Liang Z, Qin L, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial[J]. Lancet, 2022, 400(10366): 1847-1857. doi: 10.1016/S0140-6736(22)01999-7
[9] Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial[J]. JAMA, 2006, 295(13): 1519-1530. doi: 10.1001/jama.295.13.joc60038
[10] Yan Y, Gong W, Ma C, et al. Postprocedure nticoagulation in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[J]. JACC Cardiovasc Interv, 2022, 15(3): 251-263. doi: 10.1016/j.jcin.2021.11.035
[11] Yan Y, Wang X, Guo J, et al. Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J]. Am Heart J, 2020, 227: 19-30. doi: 10.1016/j.ahj.2020.06.005
[12] Yan Y, Guo J, Wang X, et al. Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial[J]. Circulation, 2024, 149(16): 1258-1267. doi: 10.1161/CIRCULATIONAHA.123.067079
[13] Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen(ASSENT)-3 PLUS randomized trial in acute myocardial infarction[J]. Circulation, 2003, 108(2): 135-142. doi: 10.1161/01.CIR.0000081659.72985.A8
[14] Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction[J]. Lancet, 2001, 358(9282): 605-613.
[15] Wallentin L, Bergstrand L, Dellborg M, et al. Low molecular weight heparin(dalteparin)compared to unfractionated heparin as an adjunct to rt-PA(alteplase)for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study[J]. Eur Heart J, 2003, 24(10): 897-908. doi: 10.1016/S0195-668X(03)00006-X
[16] Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction[J]. N Engl J Med, 2006, 354(14): 1477-1488. doi: 10.1056/NEJMoa060898
[17] Steg PG, Jolly SS, Mehta SR, et al. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial[J]. JAMA, 2010, 304(12): 1339-1349. doi: 10.1001/jama.2010.1320
[18] Blazing MA, de Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial[J]. JAMA, 2004, 292(1): 55-64. doi: 10.1001/jama.292.1.55
[19] Cohen M, Théroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin[J]. Am Heart J, 2002, 144(3): 470-477. doi: 10.1067/mhj.2002.126115
[20] Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide[J]. Circulation, 2003, 107(2): 238-244. doi: 10.1161/01.CIR.0000050144.67910.13
[21] Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial[J]. JAMA, 2004, 292(1): 45-54.
[22] Mehta SR, Yusuf S, Granger CB, et al. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes(OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes[J]. Am Heart J, 2005, 150(6): 1107.
[23] Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial[J]. J Am Coll Cardiol, 2007, 50(18): 1742-1751. doi: 10.1016/j.jacc.2007.07.042
[24] Szummer K, Oldgren J, Lindhagen L, et al. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction[J]. JAMA, 2015, 313(7): 707-716. doi: 10.1001/jama.2015.517
[25] Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy(ACUITY)trial[J]. Lancet, 2007, 369(9565): 907-919. doi: 10.1016/S0140-6736(07)60450-4
[26] Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction[J]. N Engl J Med, 2011, 365(21): 1980-1989. doi: 10.1056/NEJMoa1109596
[27] Gibson CM, Morrow DA, Murphy SA, et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial[J]. J Am Coll Cardiol, 2006, 47(12): 2364-2373. doi: 10.1016/j.jacc.2005.12.077
[28] Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin(enoxaparin)versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events[J]. J Am Coll Cardiol, 2000, 36(3): 693-698. doi: 10.1016/S0735-1097(00)00808-1
[29] Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction(TIMI)11B trial[J]. Circulation, 1999, 100(15): 1593-1601. doi: 10.1161/01.CIR.100.15.1593
[30] Dewilde WJM, Janssen PW, Kelder JC, et al. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial[J]. EuroIntervention, 2015, 11(4): 381-390. doi: 10.4244/EIJY14M06_07
[31] Kiviniemi T, Karjalainen P, Pietilä M, et al. Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention[J]. Am J Cardiol, 2012, 110(1): 30-35. doi: 10.1016/j.amjcard.2012.02.045
[32] Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38): 3720-3826. doi: 10.1093/eurheartj/ehad191
[33] White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors(SYNERGY)trial[J]. Am Heart J, 2006, 152(6): 1042-1050. doi: 10.1016/j.ahj.2006.08.002
-
计量
- 文章访问数: 229
- 施引文献: 0
下载: